Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer

Next Previous
Search
Trial Profile

PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTH 1704 (Primary) ; Odetiglucan (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Proof of concept
  • Acronyms PM-01

    • Most Recent Events

    • 30 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Sep 2014 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 08 Sep 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top